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 Drug overdose deaths increased for the 11th consecutive year causing 38,329 deaths in 
the United States in 2010, with nearly 60 percent of the those deaths (22,134) involving 
pharmaceutical drugs.  Opioid analgesics, such as oxycodone, hydrocodone, and methadone, 
were involved in about 3 of every 4 pharmaceutical overdose deaths (16,651), confirming the 
predominant role opioid analgesics play in drug overdose deaths according to an analysis from 
the CDC released in February 2013.1  
This trend continues to grow, despite opioid harm reduction strategies such as medication 
formulations that decrease methods of abuse, education initiatives (such as www.AwareRX.org, 
founded in Minnesota), public medication take-back events, proper prescribing initiatives, and 
state-run Prescription Drug Monitoring Programs.  When these efforts fail to prevent an 
overdose, a proven avenue to reduce morbidity and mortality is the use of naloxone, a pure 
opioid antagonist.  Injectable naloxone has been available in the US for more than 40 years and 
is a standard rescue medication carried by emergency medical services (EMS).  Some EMS 
programs have further developed a system to administer the injectable formulation intranasally 
via a marketed atomizer/nebulizer device, thereby decreasing concerns of transferring blood 
borne pathogens.2 
Rescue strategies are needed that reach beyond emergency response systems, thus 
becoming more accessible to the general public.  Although programs of distribution continue to 
expand across the country, nineteen (76.0%) of the 25 states with 2008 drug overdose death rates 
higher than the median and nine (69.2%) of the 13 states in the highest quartile did not have a 
community-based opioid overdose prevention program that distributed naloxone.3  Proper 
education and training is essential as the potential benefits of naloxone are temporary; 
consequently, all users are instructed to call for emergency assistance as part of standard 
protocols.  As highlighted in a recent article by Bailey et. al., community-based pharmacy 
practitioners have worked toward overcoming logistic and cultural barriers to make naloxone 
distribution for overdose a standard and acceptable practice.4   
Despite the increased recognition to improve access, some safety and ethical concerns 
have been raised in previous debates on expanded use of the medication. Health professionals 
have noted fatalities may result, especially if used by untrained people, and perhaps naloxone use 
may increase avoidance of contacting EMS.4 - 6  Though due to naloxone’s short-half life, it is 
critical to receive additional medical services after the antidote is administered as further 
“reversal” may be warranted.6  Another major obstacle has been that many states do not include 
naloxone as part “Good Samaritan” regulations protecting against legal implications when 
tending to persons in need of emergency aid.4 
In April of 2012, the FDA, the Center for Drug Evaluation and Research, the Office of the 
Assistant Secretary for Health, National Institutes of Drug Abuse, and the Centers for Disease 
Control and Prevention (CDC) sponsored a public discussion on the potential value of making 
naloxone more widely available to reduce the incidence of opioid overdose fatalities. The 
majority of individuals participating in the program were in support of an over-the-counter 
(OTC) approval of naloxone. However, several steps must occur to facilitate an OTC switch. An 
intranasal (or auto – injector) formulation would require bioequivalence studies since this current 
delivery form is off – label, as well as data to support safety, chemistry, and manufacturing. An 
OTC switch would also require usage studies to ensure patients or caregivers can understand 
directions and determine if product use is appropriate for them.5  
Pros and cons exist for an OTC naloxone. Impact from an OTC version will greatly increase 
the availability of naloxone; therefore, possibly saving thousands of lives if used correctly.  
Conversely, misuse of the product could result in deaths through lack of patient education and 
failure to contact EMS. Pharmacists play a critical role in the appropriate use of nonprescription 
medications in self-care and this may be an optimal product to be considered with the 
Nonprescription Safe Use Regulatory Expansion (NSURE) Initiative requiring a consult with the 
pharmacist prior to sale.9 
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